An observational study in Pancreatic Cancer, sponsored by Fox Chase Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2017-09-11.
Sponsored by Fox Chase Cancer Center · Observational
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is assessing fibroblast activity in patients with localized pancreatic cancer undergoing surgery.
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients undergo fine-needle aspiration of tumor or suspected mass at baseline. Tumor samples are analyzed by IHC for fibroblast activation protein (FAP) expression, immunocapture assay for ex vivo FAP enzymatic activity, and western analysis for FAP concentrations. Blood samples are collected weekly and analyzed for dipeptidyl peptidase activity by ELISA and α_2-antiplasmin converting enzyme.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's enrollment of 37 is below the median of 200 across 620 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Fox Chase Cancer Center is the lead sponsor of 211 studies on the registry; 30 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 8 (53%) have results posted.
Counted across the registry records on this site, refreshed daily.
Surgury patients scheduled to undergo a resection or exploration of their pancreatic tumor
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Independence of tumor fibroblast activation protein (FAP) activity and Met-α2-antiplasmin expression
Time frame: Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence
Feasibility of exploiting the circulatory compartment to identify surrogates of tumor FAP
Time frame: Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence
Potential plasma surrogates of plasma dipeptidyl peptidase activity and plasma antiplasmin converting enzyme
Time frame: Within 28 days for prior to surgery and at 3 month intervals for up to 2 years or recurrence
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fox Chase Cancer Center